Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tvardi Therapeutics, Inc. (TVRD : NSDQ)
 
 • Company Description   
Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $33.88 Daily Weekly Monthly
20 Day Moving Average: 20,093 shares
Shares Outstanding: 9.38 (millions)
Market Capitalization: $317.71 (millions)
Beta: 0.25
52 Week High: $36.71
52 Week Low: $8.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 42.41% 39.91%
12 Week 32.40% 20.26%
Year To Date 84.51% 72.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3 SUGAR CREEK CTR. BLVD SUITE 525
-
SUGAR LAND,TX 77478
USA		 ph: 713-489-8654
fax: 203-567-1510		 ir@tvardi.com http://www.tvarditherapeutics.com
 
 • General Corporate Information   
Officers
Christopher Posner - President; Chief Executive Officer
Ryan Maynard - Chief Financial Officer
Martin Vogelbaum - Director
Jeffrey Ives - Director
Lisa von Moltke - Director

Peer Information
Tvardi Therapeutics, Inc. (CORR.)
Tvardi Therapeutics, Inc. (RSPI)
Tvardi Therapeutics, Inc. (CGXP)
Tvardi Therapeutics, Inc. (BGEN)
Tvardi Therapeutics, Inc. (GTBP)
Tvardi Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 140755307
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/13/25
Share - Related Items
Shares Outstanding: 9.38
Most Recent Split Date: 4.00 (0.33:1)
Beta: 0.25
Market Capitalization: $317.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.63
Price/Cash Flow: -
Price / Sales: 37.11
EPS Growth
vs. Year Ago Period: 92.50%
vs. Previous Quarter: 68.94%
Sales Growth
vs. Year Ago Period: 20.33%
vs. Previous Quarter: 5.03%
ROE
06/30/25 - -565.83
03/31/25 - -
12/31/24 - -849.09
ROA
06/30/25 - -66.71
03/31/25 - -104.25
12/31/24 - -123.58
Current Ratio
06/30/25 - 4.04
03/31/25 - 32.48
12/31/24 - 11.03
Quick Ratio
06/30/25 - 4.04
03/31/25 - 31.73
12/31/24 - 10.81
Operating Margin
06/30/25 - -
03/31/25 - -628.87
12/31/24 - -979.75
Net Margin
06/30/25 - -
03/31/25 - -678.79
12/31/24 - -1,032.33
Pre-Tax Margin
06/30/25 - -453.48
03/31/25 - -531.13
12/31/24 - -998.53
Book Value
06/30/25 - 3.52
03/31/25 - -2.59
12/31/24 - -3.02
Inventory Turnover
06/30/25 - 0.00
03/31/25 - 0.00
12/31/24 - 0.42
Debt-to-Equity
06/30/25 - 0.00
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - 0.00
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©